Afte Prothena announced its CEO was taking a medical leave and that it was elevating its COO, Gene Kinney, to interim CEO, RBC Capital analyst Michael Yee says "this a a neutral and natural positive development." Yee reports that Kinney " has been generally in charge of and overseen the R&D and clinical development of their 3 lead programs and involved in leading discussions with the FDA." The analyst believes that the company had previously been planning for succession and that investors should not be surprised by this development, as they knew that the CEO had health problems. Yee keeps an Outperform rating on the shares.